ASTRAZEN

AstraZeneca Pharma India has reached a significant milestone, hitting a new 52-week high of Rs. 10,050 on June 6, 2025. This achievement reflects the company's strong performance in the pharmaceuticals and biotechnology sector. Over the past year, AstraZeneca Pharma India has delivered impressive returns of 57.08%, significantly outperforming the Sensex, which has seen a return of 8.24%. The company has demonstrated robust financial health, with a remarkable net profit growth of 88.82% reported in March 2025. Additionally, AstraZeneca boasts a high return on equity (ROE) of 19.06% and a low debt-to-equity ratio, indicating strong management efficiency. Despite a slight underperformance today, the stock remains technically bullish, trading above its moving averages. AstraZeneca Pharma India continues to be recognized among the top 1% of companies solidifying its position as a leader in the large-cap segment of the market.